1. Aortic regurgitation with second versus third-generation balloon-expandable prostheses in patients undergoing transcatheter aortic valve implantation
- Author
-
Hans D. Theiss, Julinda Mehilli, Axel Bauer, Steffen Massberg, Moritz Baquet, Magda Zadrozny, Christian Hagl, Fatima Maimer-Rodrigues, Philipp S. Lange, Jörg Hausleiter, Christian Kupatt, David Jochheim, and Martin Greif
- Subjects
Male ,medicine.medical_specialty ,Cardiac Catheterization ,Transcatheter aortic ,medicine.medical_treatment ,Aortic Valve Insufficiency ,Regurgitation (circulation) ,Prosthesis ,Transcatheter Aortic Valve Replacement ,Internal medicine ,medicine ,Humans ,In patient ,Aged ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,Bundle branch block ,business.industry ,Incidence (epidemiology) ,Incidence ,Odds ratio ,Aortic Valve Stenosis ,Middle Aged ,medicine.disease ,Surgery ,Balloon expandable stent ,Treatment Outcome ,Heart Valve Prosthesis ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
AIMS Our aim was to assess the incidence of aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) with the second (SXT) versus third-generation (S3) balloon-expandable SAPIEN prosthesis in patients with symptomatic aortic stenosis (AS). METHODS AND RESULTS Of 634 patients undergoing TAVI in our centre from May 2010 to July 2014, 354 were treated with the SXT and 100 with the S3 prosthesis. The primary outcome was the incidence of more-than-mild post-TAVI AR at discharge. Secondary outcomes were 30-day incidence of all-cause death, any bleeding complications and need for new pacemaker. The incidence of the primary outcome was 2.0% vs. 8.8%, p
- Published
- 2015